Nykredit A S Invests $5.45 Million in Insulet Corporation $PODD

Nykredit A S acquired a new position in shares of Insulet Corporation (NASDAQ:PODD) in the second quarter, HoldingsChannel reports. The fund acquired 35,795 shares of the medical instruments supplier’s stock, valued at approximately $5,450,000.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the stock. Larson Financial Group LLC boosted its holdings in Insulet by 114.6% during the fourth quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier’s stock worth $25,000 after buying an additional 47 shares during the last quarter. University of Texas Texas AM Investment Management Co. bought a new stake in shares of Insulet in the 4th quarter valued at about $26,000. Elyxium Wealth LLC acquired a new stake in shares of Insulet in the 4th quarter valued at approximately $28,000. DV Equities LLC acquired a new stake in shares of Insulet in the 4th quarter valued at approximately $28,000. Finally, MV Capital Management Inc. bought a new position in Insulet during the 4th quarter worth approximately $29,000.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on PODD. Wall Street Zen cut shares of Insulet from a “strong-buy” rating to a “hold” rating in a report on Sunday, August 9th. JPMorgan Chase & Co. reiterated a “neutral” rating and issued a $152.00 target price (down from $275.00) on shares of Insulet in a report on Thursday, August 6th. The Goldman Sachs Group reissued a “buy” rating and set a $205.00 price target on shares of Insulet in a research report on Wednesday, May 27th. Truist Financial reissued a “hold” rating and issued a $153.00 price target (down from $210.00) on shares of Insulet in a report on Wednesday, August 5th. Finally, Evercore set a $180.00 price objective on shares of Insulet in a research report on Monday, July 6th. Fourteen research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $195.40.

Insulet Price Performance

NASDAQ PODD opened at $147.48 on Monday. The business has a 50 day simple moving average of $154.45 and a 200 day simple moving average of $177.27. Insulet Corporation has a 52-week low of $126.40 and a 52-week high of $354.88. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.83 and a current ratio of 2.48. The stock has a market cap of $10.23 billion, a price-to-earnings ratio of 27.57, a PEG ratio of 1.16 and a beta of 1.08.

Insulet (NASDAQ:PODD) last announced its quarterly earnings results on Wednesday, August 5th. The medical instruments supplier reported $1.66 earnings per share for the quarter, beating analysts’ consensus estimates of $1.47 by $0.19. The firm had revenue of $801.70 million for the quarter, compared to analyst estimates of $787.39 million. Insulet had a net margin of 12.29% and a return on equity of 29.29%. The business’s revenue was up 23.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.17 earnings per share. Insulet has set its FY 2026 guidance at 6.460- EPS. Analysts anticipate that Insulet Corporation will post 6.51 earnings per share for the current fiscal year.

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.